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Abstract
Background: Ivabradine, a selective bradycardic drug, inhibits the If. In patients with heart 
failure (HF), ivabradine reduces the risk of rehospitalization and mortality. The average heart 
rate (HR) reduction is 8–10 beats, although clinical trials reveal interindividual variability. 
The aim of the study is to identify variants associated with HR reduction produced by ivabra-
dine in genes involved in the drug metabolism (CYP3A4) or related to the drug target (HCN4).
Methods: In an exploratory cohort (n = 11), patients started on ivabradine were genotyped 
and the HR reduction was studied.
Results: The mean HR reduction after the treatment was 18.10 ± 12.26 bpm. The HR reduc-
tion was ≥ 15 bpm in 3 patients and > 5 and < 15 bpm in 7 patients. Four synonymous vari-
ants, L12L, L520L, P852P, and P1200P, were detected in the HCN4 gene (frequency = 0.045, 
0.045, and 0.681, respectively). Moreover, the CYP3A4*1F and CYP3A4*1B were found in 
one patient each and CYP3A4*1G was presented in 3 patients.
Conclusions: This is the first study using an exploratory pharmacogenetic approach that 
attempts to explain interindividual variability in ivabradine HR reduction. However, more 
research must be undertaken in order to determine the role of variants in HCN4 and CYP3A4 
genes in response to ivabradine. (Cardiol J 2016; 23, 5: 573–582)
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Introduction
Heart failure (HF) is defined as a syndrome 
in which patients show typical symptoms (e.g. 
breathlessness, ankle swelling, and fatigue) and 
signs (e.g. elevated jugular venous pressure, pul-
monary crackles, and displaced apex beat) resulting 
from an abnormal cardiac structure or function [1]. 
Approximately 1–2% of the adult population in 
developed countries has HF, with the prevalence 
rising to ≥ 10% among individuals aged 70 or over.
Heart failure remains a disabling disorder that 
can severely affect patients’ quality of life. How-
ever, there is a crucial need for the development 
of innovative therapeutic approaches [2].
One strategy is the control of the heart rate 
(HR) in HF patients. Ivabradine, which slows the 
heart by selective If current inhibition with no other 
cardiovascular effects, has been approved by the 
European Medicines Agency for this purpose, fol-
lowing the BEAUTIFUL and SHIFT trials [3, 4]. 
The SHIFT trial showed that HR reduction with 
ivabradine significantly reduced adverse clinical 
outcomes in a population with symptomatic HF 
and HR ≥ 70 bpm [4]. However, the magnitude of 
HR reduction achieved with ivabradine displays 
considerable interindividual variability [4]. In fact, 
in a pre-specified subgroup of SHIFT, the reduction 
in HR at 28 days was £ 5 bpm in 21% of patients, 
> 5 and < 15 bpm in 34% of patients, and ≥ 15 bpm 
in 41% of patients [5]. The effect of ivabradine 
is known to be influenced by the HR at baseline. 
However, other factors, such as genetic variations, 
may play a role in the magnitude of HR reduction 
achieved with ivabradine, although to date this 
hypothesis has not been addressed.
On the basis of mechanism of action and phar-
macokinetics of ivabradine, HCN4, which encodes 
isoform 4 of hyperpolarization-activated cyclic 
nucleotide-gated channels, whose proteins are 
the a-subunits of the channel generating the If cur-
rent  [6], and CYP3A4, which encodes the isoform 
3A4 of the cytochrome P450, the main enzyme re-
sponsible for the metabolism of ivabradine [7], could 
be candidate genes to present variants that could be 
associated with differential responses to ivabradine.
The ivabradine binding site has recently been 
located within the inner cavity of HCN4 channels 
(Y506, F509, and I510), where the bound ivabra-
dine is stabilized by several Van der Waals and 
hydrophobic interactions [6]. Several HCN4 vari-
ants modifying the If current have been described 
[8–10]. Moreover, the importance of HCN4 variants 
has been recently described because a new locus 
near HCN4 gene has been associated with HR [11]. 
However, the effect of HCN4 variants as modifiers 
of the response to ivabradine has not been studied.
It is known that 80% of ivabradine metabolic 
clearance is done through the cytochrome P450 
isoform 3A4 (CYP3A4) [7]. Nowadays, more than 
40 single nucleotide polymorphisms (SNPs) in 
the CYP3A4 gene have been identified with vary-
ing functional effects [12]. The CYP3A4*1G SNP 
(rs2242480), also known as IVS10+12G>A, can 
increase the activity of the CYP3A4 enzyme [12, 
13], whereas CYP3A4*22 (rs35599367) has been 
associated with reduced CYP3A4 activity [14, 15]. 
The functional effect of CYP3A4*1B (rs2740574) is 
controversial [14] because it has been associated 
with an enhanced CYP3A4 expression due to the 
reduced binding of a transcriptional repressor [16] 
as well as a reduction in CYP3A4 activity [17].
Therefore, it is important to determine the 
potential role of variants in the HCN4 and CYP3A4 
genes in response to treatment with ivabradine. 
Thus, the objective of this study was to screen 
for variants in the entire codified region of the 
HCN4 gene and in three particular SNPs in the 
CYP3A4 gene which could affect the interindividual 
variability found in the magnitude of HR reduction 
achieved with ivabradine.
Methods
Patients
The study was carried out on 11 patients 
from the Advanced Heart Failure and Transplant 
Unit of the Complejo Hospitalario Universitario 
de A Coruña (CHUAC) with HF, reduced ejection 
fraction (£ 35%), sinus rhythm, HR > 70 bpm and 
New York Heart Association (NYHA) class II–IV, 
and in whom ivabradine therapy had been initiated 
(Table 1). Blood samples for DNA analysis were 
taken concomitantly with blood tests for clinical 
monitoring. Two 24 h Holter electrocardiogram 
(ECG) recordings were taken, the first prior to 
ivabradine therapy and the second 15 days later. 
Mean HR reduction between the 2 Holter studies 
was calculated. The study was approved by the 
“Comité ético de investigación de Galicia” (Refe-
rence: 2012/323) and conforms to the ethical 
guidelines of the Declaration of Helsinki. Informed 
consent was obtained for both the samples and the 
genetic screening tests.
Genetic study
Genomic DNA was isolated from peripheral 
blood samples using IllustraTM DNA Extraction Kit 
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BACC3 (GE Healthcare), as previously described 
[18, 19]. The variant analysis was carried out by 
a polymerase chain reaction (PCR) followed by 
direct sequencing [18, 19]. The primers were de-
signed using Primer3 software (http://bioinfo.ut.ee/ 
/primer3-0.4.0/) (Table 2). The entire codifying 
sequence and the flanking intronic regions of the 
HCN4 gene were amplified by PCR. Three CYP3A4 
SNPs, previously described with a functional ef-
fect (*1B,*1G,*22), were analyzed. A further SNP, 
*1F (rs11773597), was analyzed due to its inclu-
sion in the amplicon design for the screening of 
CYP3A4*1B. The sequences were compared with 
the reference genomic sequence of the genes using 
Variant Reporter 1.0 (Applied Biosystem).
In silico tools
Localization: The topological placement of 
the mutations was carried out using the Swiss-Prot 
database (http://ca.expasy.org/uniprot/).
Splice site score predictions
The NNSplice (http://www.fruitfly.org/ 
seq_tools/splice.html [20]), NetGene2 (http://www.
cbs.dtu.dk/services/NetGene2/ [21]), and HSF 
(http://www.umd.be/HSF/ [22]) programs were 
used to predict whether the exon changes could 
affect splice-enhancing sequences.
Results
Clinical characteristics of the patients  
and response to ivabradine
A summary of the patients’ clinical character-
istics is given in Table 1. Two patients discontin-
ued the treatment with ivabradine due to adverse 
drug-related events. One patient (No. 3) described 
gastrointestinal disorders, a stifling sensation, dys-
pnea and rubefaction on day 11 of the treatment. 
Another patient (No. 6) stopped the treatment after 
2 months due to low HR-related asthenia.
Table 2. Primers used in the study.
Fragment Primer sequence (5’Æ3’) Amplicon size
HCN4 Ex1_F GACTCGGAGCGGGACTAGGAT 1078 nt
HCN4 Ex1_R CCAGCGCAAGGCAGGAAAGTT
HCN4 Ex2_F CCAGATGCTGTCCCTCAGAT 576 nt
HCN4 Ex2_R CCAGTTCCTCACTCCCTCTG
HCN4 Ex3_F CAGAGTCCAGGCAGAGCAGT 377 nt
HCN4 Ex3_R GGTCCTACATGCTGGAACTCA
HCN4 Ex4_F CTTTCAGCCAACAGCAAGGT 496 nt
HCN4 Ex4_R TTCCCTCACACTGGGAGTTC
HCN4 Ex5+6_F GGAACCAAGTTTAGCCAGGA 695 nt
HCN4 Ex5+6_R GCCTCTGTCCCCTCGGTAT
HCN4 Ex7_F TTCTGTGCCAGGCAGTCA 361 nt
HCN4 Ex7_R GGAAGGAGATCAGGTGCAGA
HCN4 Ex8A_F CTTTATGCCTAAGCCAGGTCT 847 nt
HCN4 Ex8A_R CTAGATGACGGGGATCTGGA
HCN4 Ex8B1_F AACAGCTGGCTGGATTCTCTGC 578 nt
HCN4 Ex8B1_R CAAGGATCCGTGGGAGCCAGA 
HCN4 Ex8C_F CTTCCCCTGTAGGCTTTACTC 724 nt
HCN4 Ex8C_R CCTGGTTATTTTCTGCTGTCTT
CYP3A4*1B_F CCAACAGAATCACAGAGGACCAGC 908 nt
CYP3A4*1B_R CTCTGAGTCTTCCTTTCAGCTCTGTGT
CYP3A4*22 Ex7_F CCCATCTTGTATCATCCACAA 466 nt
CYP3A4*22 Ex7_R TGAGAGAAAGAATGGATCCAAAA
CYP3A4*1G Ex10_F AGGGATTTGAGGGCTTCACT 399 nt
CYP3A4*1G Ex10_R TTTCTTTTCAGAGCCTTCCTACA
These primers were designed using the reference sequence from GenBank-GRCh37.p9 [HCN4: NC_000015.9 (73612200..73661605); CYP3A4: 
NC_000007.13 (99354583…99382811)] and Primer3 software.
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The mean reduction of HR after treatment 
with ivabradine was 18.10 ± 12.26 bpm. Using the 
subgroup classification applied to a sub-study of the 
SHIFT study, the HR reduction was shown to be 
≥ 15 bpm in 3 patients and 5–15 bpm in 7 patients. 
None of our patients showed an HR reduction of 
£ 5 bpm.
Variants found in the HCN4 gene
As shown in Table 3, Figures 1A and 2A–D, 
4 synonymous single nucleotide variants were found 
in the HCN4 gene. c.36C>G (L12L), c.1558C>T 
(L520L) and c.2256G>A (P852P) were each found 
in heterocygosity in 1 patient. Thus, the minor al-
lele frequency (MAF) in our cohort of each variant 
Table 3. Variants found in the cohort in HCN4 gene and variants studied in CYP3A4 gene.
Patient no. Variants found in HCN4 gene
1 g.46772A>G (p.P1200P)
2 g.46772G (p.P1200P)
3 g.39660C>T (p.L520L)
4 g.46772G (p.P1200P)
5 g.1030C>G (p.L12L), g.46772A>G (p.P1200P)
6 g.45728G>C (p.P852P), g.46772G (p.P1200P)
7 g.46772G (p.P1200P)
8 g.46772G (p.P1200P)
9 g.46772G (p.P1200P)
10 None
11 g.46772A>G (p.P1200P)
CYP3A4 1 2 3 4 5 6 7 8 9 10 11
CYP3A4*1F CC CC CC CC CC CG CC CC CC CC CC
CYP3A4*1B AA AA AA AA AA AA AG AA AA AA AA
CYP3A4*22 CC CC CC CC CC CC CC CC CC CC CC
CYP3A4*1G GG GG GA GA GG GG AA GG GG GG GG
Figure 1. A. Schematic structure of the HCN4 channel showing the variants identified in the present study; B. Sche-
matic structure of the human CYP3A4 gene showing the four single nucleotide polymorphisms analyzed in the present 
study, which produce variations in normal functioning of cytochromes.
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is 0.045. The other variant found was c.3600A>G 
(P1200P), and it was present in 3 patients in hete-
rozygosity and in 6 patients in homozygosity. Thus, 
the P1200P MAF in our cohort is 0.682.
In silico analysis of the variants  
found in the HCN4 gene
Although 3 programs used failed to detect any 
impact on the corresponding natural splice site for 
the 4 variants studied, these variants could modify 
the exonic splicing enhancer and the silencer mo-
tifs (Table 4).
The variant c.36C>G (L12L) is predicted to 
create a new site as an exonic splicing enhancer 
(ESE) to link the Ser/Arg-rich (SR) protein SF2/ASF. 
Moreover, using the Sironi method, L12L is pre-
dicted to produce a ‘site broken’ of a silencer motif.
The ESE finder software predicted a ‘site 
broken’ when the variant c.1558C>T (L520L) was 
present for the Srp40 and SF2/ASF SR proteins. 
The putative exonic splicing enhancer (PESE) 
software predicted a new site and a ‘site broken’ in 
the presence of the L520L, but the motif values, in 
both cases, were low. Analysis of silencer motifs re-
vealed a ‘site broken’ when the L520L was present.
Two programs used in the in silico analysis 
detected a new site as ESE for the c.2256G>A 
(P852P) variant.
Figure 2. A–D. Electropherograms of the variants identified in the HCN4 gene; E–G. Electropherograms of two of the 
four single nucleotide polymorphisms analyzed in the CYP3A4 gene where minor alleles are presented.
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Moreover, two of the programs predicted that 
the variant c.3600A>G (P1200P) could create 
a new site for binding the SC35 and 9G8 proteins, 
whereas the RESCUE ESE predicted a ‘site bro-
ken’ of an exonic splicing enhancer.
The prediction for the variants L12L, L520L, 
and P1200P were the presence of several ‘sites 
broken’ in silencer motifs.
SNPs distribution in the CYP3A4 gene
Figure 1B shows the SNPs analyzed in our 
patients. Table 3 and Figure 2E–G show the geno-
types of the 11 patients for the 4 variants ana-
lyzed. CYP3A4*1F SNP was found in 1 patient; 
CYP3A4*1B SNP in another; and the variant 
CYP3A4*1G in 3, 2 of them presented the variant 
in heterozygosity and one in homozygosity. The 
Table 4. In silico analysis of exonic splicing enhancer (ESE) and silencer motifs of the variants found in 
the HCN4 gene.
*ESE finder matrices for SRp40, SC35, SF2/ASF and SRp55
Variant Reference motif Mutant motif Variation
Linked SR  
protein
Reference motif 
(value 0–100)
Linked SR  
protein
Reference motif 
(value 0–100)
p.L12L SF2/ASF  
(IgM-BRCA1)
cggctgt (78.23) New site
SF2/ASF cggctgt (73.44) New site
p.L520L SRp40 tccctgg (84.13) Site broken
SF2/ASF  
(IgM-BRCA1)
ccctgga (84.13) Site broken
p.P1200P SC35 aactgccg (76.21) New site
*RESCUE ESE hexamers
Variant Reference motif Mutant motif Variation
p.P852P atcttc New site
p.P1200P atccaa Site broken
*Predicted PESE Octamers from Zhang & Chasin
Variant Reference motif Mutant motif Variation
Reference  
motif 
Motif value 
(0–100)
Reference  
motif 
Motif value 
(0–100)
p.L520L ccagtcct 38.75 New site
tccctgga 42.96 Site broken
p.P852P acaccatc 29.64 New site
*ESE motifs from HSF
Variant Reference motif Mutant motif Variation
Linked ESE  
protein
Reference motif 
(value 0–100)
Linked ESE  
protein
Reference motif 
(value 0–100)
p.P1200P 9G8 gccgtc (62,82) New site
*Silencer motifs from Sironi et al.
Variant Reference motif Mutant motif Variation
Sironi motif  
reference
Reference silen-
cer (value 0–100)
Sironi mutant 
motif 
Mutant silencer 
(value 0–100)
p.L12L Motif 1: CTAGAGGT ctacagcc (67.64) Site broken 
(13.49)
p.L520L Motif 3: TCTCCCAA agtccctg (69.14) Site broken 
(–0.16)
p.P1200P Motif 3: TCTCCCAA actgccat (72.52) Site broken 
(11.26)
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MAF in our cohort for *1F, *1B, and *1G are 0.045, 
0.045, and 0.182, respectively.
Discussion
Knowledge regarding the genetic basis of dif-
ferential therapeutic drug response has generated 
hope for individually tailored drug therapy. Interin-
dividual differences in drug metabolism, distribu-
tion and excretion, and drug targets (receptors) 
are important considerations in assessing drug 
efficacy, safety, and dose [23]. Thus, in the case of 
ivabradine, it is important to study the variants in 
the CYP3A4 and HCN4 genes, as they both codify 
the proteins involved in its metabolism and relate 
to the drug target. This study identifies four syn-
onymous variants in the HCN4 gene (L12L, L520L, 
P852P, and P1200P) and two SNPs in the CYP3A4 
gene (CYP3A4*1F and CYP3A4*1G).
Clinical data
This exploratory analysis studies the effect 
of ivabradine in 11 patients. The distribution of no 
responders (n = 0), poor responders (n = 7), and 
high responders (n = 3) is not homogeneous. In 
a number of studies [4, 5], the effects of ivabradine 
were found to be greater in patients with higher 
baseline HR due to the use-dependent block. Our 
results also showed that it is important to analyze 
the baseline HR in order to study the HR reduction 
produced by ivabradine. As shown in Table 1, in 
5 out of 11 patients, the baseline HR was 70–80 bpm; 
in 4 out of 11, the baseline HR was 81–90 bpm; 
and in 2 out of 11, the baseline HR was higher than 
91 bpm. In line with the above, the biggest reduction 
was obtained in patients with the highest baseline 
HR; in our cohort, these were patients no. 7 and 
no. 11, in whom the HR reduction after ivabradine 
treatment was 23 and 53 bpm, respectively.
Two out of 11 patients (Table 1) were with-
drawn from the treatment during the study; one 
prior to the second Holter recording and the second 
after 2 months due to low HR-related asthenia. In 
previous trials [3, 4, 24], withdrawal rates were be-
tween 4% and 28%. If we focus on withdrawal rates 
due to an adverse event, the figures range between 
1.7% and 13.2% [3, 4, 24, 25]. The percentage of 
withdrawals in our exploratory study was 18.2%, 
within the range given above, although it is higher 
than the adverse event withdrawal rate.
However, it is important to note that this is 
an exploratory prospective study on consecutive 
patients. A large-scale multicenter study would be 
required in order to analyze in greater depth the ef-
fects of polymorphism in ivabradine treatment and 
reach relevant conclusions about relation of variants 
in CYP3A4 and HCN4 genes on ivabradine HR.
Distribution of mutations in the cohort
The synonymous variants found in the HCN4 
gene in our cohort are included in the Single 
Nucleotide Polymorphism Database (dbSNP) 
and the MAFs described in dbSNP were 0.011, 
0.053, 0.023, and 0.131 for the variants L12L 
(rs201193660), L520L (rs12909882), P852P 
(rs117819825), and P1200P (rs529004), respec-
tively. In our cohort, the variants L12L, L520L, 
and P852P were found in one patient each. Thus, 
the MAFs for these variants were 0.045, similar to 
those previously described. However, the MAF in 
our cohort for the variant P1200P is 0.682, which 
is far higher than that described in dbSNP. In fact, 
in our cohort, the minor allele is c.3600A and not 
c.3600G, as is described in literature and in the 
sequence.
Point variants in the coding regions of genes 
were traditionally assumed to act by altering single 
amino acids in the encoded proteins. Consequently, 
the synonymous mutations detected in genetic 
screens are presumed to be neutral. However, 
translationally silent mutations can disrupt ESEs 
or exonic splicing silencers (ESSs) and cause an 
alteration in the splicing machinery, with dra-
matic effects on the structure of the gene product 
[26–28]. ESEs represent binding sites for proteins 
with long repeats of serine and arginine amino acid 
residues (SR proteins), which are believed to play 
a role in the initial steps of spliceosome assembly, 
whilst ESSs have been shown to bind negative 
regulators belonging to the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family [27, 28]. The 
function of ESEs and ESSs appears to be especially 
important for the regulation of alternative splicing 
events, yet these sequences probably also play 
a relevant role in defining constitutive exons [27, 28]. 
Therefore, in this study, we performed an in silico 
analysis in order to detect the two major classes of 
cis-regulator of splicing, ESEs and ESSs.
Two variants found in this study, L12L and 
P852P, were predicted to produce an ESE creation, 
where predicted ESEs are present in the variant 
but not in the wild-type sequence. The other two 
variants, L520L and P1200P, were predicted to pro-
duce ESE creation and ESE disruptions, where one 
or more predicted ESEs present in the wild-type 
sequence are disrupted by the variants. Moreo-
ver, the software used predicted a ‘site broken’ 
for a silencer motif for the variants L12L, L520L, 
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and P1200P. Consequently, and as addressed by 
the biocomputational approach, the four variants 
found in the HCN4 gene could alter the splicing 
machinery. However, the presence of a score 
motif in a sequence does not necessarily identify 
that sequence as a functional ESE or ESS, which 
indicates not a very strict quantitative correlation 
between numerical score and ESE or ESS activ-
ity [26]. Until stronger predictive algorithms are 
available, direct experimental evidence will remain 
necessary before drawing a safe conclusion that 
a particular sequence can act as an ESE or ESS in 
its natural context [26]. In addition, assessing the 
clinical impact of these variants is a complex task 
since each three of the variants are present in one 
patient only, whilst P1200P is presented in 9 of 
11 patients studied. However, it has been shown that 
ivabradine reduced the HR by 13 bpm in a patient 
carrying the L12L variant. A patient with L520L 
discontinued the treatment due to adverse events; 
and in the case of a patient carrying P852P variant 
the HR was reduced by 11 bpm. It is important 
to note that patients carrying the L12L and the 
P852P variants also carried the P1200P variant 
and the presence of more than one variant further 
complicates the interpretation of the data.
In the case of SNPs studied in the CYP3A4 
gene, we found the CYP3A4*1F in 1 patient in 
heterozygosity (MAF = 0.045); CYP3A4*1B in 
1 patient in heterozygosity (MAF = 0.045); and 
CYP3A4*1G in 2 patients in heterozygosity and 
in 1 patient in homozygosity (MAF = 0.182). The 
frequencies of CYP3A4*1F are similar to those 
previously described in dbSNP (0.036). However, 
the frequencies found in our cohort for the vari-
ants CYP3A4*1B and CYP3A4*1G are lower than 
those previously described in dbSNP, being 0.201 
and 0.334, respectively.
In our cohort, CYP3A4*1F is present in 
1 patient who experienced an 11 bpm reduction in 
HR after 15 days of treatment with ivabradine. 
CYP3A4*1F is a variant in the 5’ regulatory region 
of the gene and it leads to a new CpG island that 
can be methylated [29]. This potential methylation 
position could be significant for the function of this 
enzyme. To date, no particular phenotype has been 
associated with this allele [29, 30]. Further re-
search is therefore necessary in order to assess the 
role of CYP3A4*1F in the function of the enzyme.
CYP3A4*1B was found in heterozygosity in 
1 patient whose HR was reduced by 11 bpm following 
treatment with ivabradine. The functional effect of 
this SNP has not been established because it has 
been associated not only with an enhanced CYP3A4 
expression due to reduced binding of a transcrip-
tional repressor [16] but also with a reduced level 
of CYP3A4 activity [17]. Thus, further clinical and 
basic research is required in order to assess the 
role of the CYP3A4*1B.
CYP3A4*1G SNP has been described as a vari-
ant that can increase CYP3A4 activity [12, 13]. In 
our cohort, 2 patients have this variant in heterozy-
gosity and 1 patient in homozygosity. The reduction 
after treatment with ivabradine was 14 bpm in 
1 patient with the variant in heterozygosity, and 
23 bpm in a patient with the variant in homozygosity. 
The second patient with the variant discontinued 
the treatment due to adverse events. CYP3A4*1G 
therefore appears to have insufficient impact on the 
metabolism of ivabradine as the 2 patients analyzed 
are good responders.
The role of variants in the response  
to ivabradine
Inherited genetic differences may result in the 
identification of sub-groups of patients, including 
those who are good responders, poor responders 
and those likely to present adverse drug reactions 
[23]. In our exploratory cohort, no poor respond-
ers were detected. HR was ≥ 15 bpm in 3 patients 
and > 5 and < 15 bpm in 7 patients, and 2 patients 
discontinued the treatment due to adverse events. 
Variant distribution in this small-size cohort of this 
exploratory study does not allow the variants to be 
correlated with these sub-groups. Consequently, 
further research is required in order to assess the 
role of variants in the CYP3A4 and HCN4 genes 
in ivabradine treatment.
Conclusions
This study has identified 4 synonymous 
variants in the HCN4 gene and 3 SNPs in the 
CYP3A4 gene. None of the variants appear to have 
a major effect on the reduction of HR produced by 
ivabradine. However, and due to the limited size 
of the cohort, further research must be carried 
out in order to determine the role of different 
variants in HCN4 and CYP3A4 genes in response 
to ivabradine.
Moreover, the in silico analysis must be given 
due consideration, as when isolated from other 
experimental data, it fails to provide sufficient 
information in terms of genetic counselling.
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